Compare Nvidia Corp (NVDA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs BIO-TECHNE Corp — how do they compare? Nvidia Corp trades at $223.18 (market cap $5.45T), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Nvidia Corp is far larger — about 480.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp is trading nearer its 52-week high, Nvidia Corp nearer its low. Which is the better fit depends on your goals.
| NVDA | TECH | |
|---|---|---|
Market Cap | $5.45T | $11.34B |
Sector | Technology | Health |
52-Week High | $235.75 | $72.48 |
52-Week Low | $165.17 | $43.31 |
Enterprise Value | $5.43T | $11.36B |
Dividend Yield | 0.44% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $225.73, down 2.01% over the past day, amid a broader tech sell-off. The stock maintains a bullish technical signal with strong moving average support, while oscillators are neutral. Fundamentally, the company reported robust revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $344.10 implying significant upside.
Outlook: NVDA's leadership in AI chips and accelerating revenue growth present a compelling investment case, though risks include heightened competition and potential market saturation. The stock's current valuation metrics, such as a P/E of 28.54, appear reasonable given its growth trajectory. Institutional ownership trends and strong cash flow generation support long-term bullish sentiment, but investors should monitor execution risks and macroeconomic headwinds.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
